This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery
Scientist-led competitive selection deepens BenchSci’s presence in European biopharma TORONTO — BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci’s agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
In this story
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 25 minutes later, on .
Filed under General · Canada · News. Topics extracted from this report, with other live CurrentWire stories mentioning each: Toronto (11), Artificial Intelligence (37), Two-Year Enterprise Agreement (none), Advance AI-Driven Preclinical Drug Discovery (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.